In colorectal cancer (CRC), KRAS mutational status is critical for targeted therapy (5) because it can predict the therapeutic response to anti-epidermal growth factor receptor (EGFR) treatment; consequently, KRAS genotyping is routine in patients with metastatic CRC. The gene discussed is KRAS; the disease is colorectal cancer.